OBJECTIVE: To evaluate changes in structural damage and joint inflammation assessed by MRI following rituximab treatment in a Phase 3 study of patients with active rheumatoid arthritis (RA) despite methotrexate (MTX) who were naive to biological therapy. METHODS: Patients were randomised to receive two infusions of placebo (n=63), rituximab 500 mg (n=62), or rituximab 1000 mg (n=60) intravenously on days 1 and 15. MRI scans and radiographs of the most inflamed hand and wrist were acquired at baseline, weeks 12 (MRI only), 24 and 52. The primary end point was the change in MRI erosion score from baseline at week 24. RESULTS: Patients treated with rituximab demonstrated significantly less progression in the mean MRI erosion score compared with those treated with placebo at weeks 24 (0.47, 0.18 and 1.60, respectively, p=0.003 and p=0.001 for the two rituximab doses vs placebo) and 52 (-0.30, 0.11 and 3.02, respectively; p<0.001 and p<0.001). Cartilage loss at 52 weeks was significantly reduced in the rituximab group compared with the placebo group. Other secondary end points of synovitis and osteitis improved significantly with rituximab compared with placebo as early as 12 weeks and improved further at weeks 24 and 52. CONCLUSIONS: This study demonstrated that rituximab significantly reduced erosion and cartilage loss at week 24 and week 52 in MTX-inadequate responder patients with active RA, suggesting that MRI is a valuable tool for assessing inflammatory and structural damage in patients with established RA receiving rituximab. TRIAL REGISTRATION NUMBER: NCT00578305.

*Academic Medical Center University of Amsterdam Amsterdam The Netherlands; *Current address also University of Cambridge Cambridge UK and GlaxoSmithKline Stevenage UK

Charles University Prague Czech Republic

Copenhagen Center for Arthritis Research Center for Rheumatology and Spine Diseases Glostrup Hospital University of Copenhagen Copenhagen Denmark

F Hoffmann La Roche Ltd Basel Switzerland

Hospital Universitario Seville Spain

Leeds Institute of Rheumatic and Musculoskeletal Medicine University of Leeds and NIHR Leeds Musculoskeletal Biomedical Research Unit Leeds Teaching Hospitals NHS Trust Leeds UK

Spire Sciences Inc Boca Raton Florida USA

Tallinn Central Hospital Tallinn Estonia

See more in PubMed

Colebatch AN, Edwards CJ, Ostergaard M, et al. . EULAR recommendations for the use of imaging of the joints in the clinical management of rheumatoid arthritis. Ann Rheum Dis 2013;72:804–14. PubMed

Cohen SB, Keystone E, Genovese MC, et al. . Continued inhibition of structural damage over 2 years in patients with rheumatoid arthritis treated with rituximab in combination with methotrexate. Ann Rheum Dis 2010;69:1158–61. PubMed PMC

Tak PP, Rigby W, Rubbert-Roth A, et al. . Sustained inhibition of progressive joint damage with rituximab plus methotrexate in early active rheumatoid arthritis: 2-year results from the randomised controlled trial IMAGE. Ann Rheum Dis 2012;71:351–7. PubMed PMC

Landewe RB, Boers M, Verhoeven AC, et al. . COBRA combination therapy in patients with early rheumatoid arthritis: Long-term structural benefits of a brief intervention. Arthritis Rheum 2002;46:347–56. PubMed

Keystone EC, Cohen SB, Emery P, et al. . Multiple courses of rituximab produce sustained clinical and radiographic efficacy and safety in patients with rheumatoid arthritis and an inadequate response to 1 or more tumor necrosis factor inhibitors: 5-year data from the REFLEX study. J Rheumatol 2012;39:2238–46. PubMed

Ostergaard M, Peterfy C, Conaghan P, et al. . OMERACT rheumatoid arthritis magnetic resonance imaging studies. core set of MRI acquisitions, joint pathology definitions, and the OMERACT RA-MRI scoring system. J Rheumatol 2003;30:1385–6. PubMed

American College of Rheumatology Rheumatoid Arthritis Clinical Trials Task Force Imaging Group and Outcome Measures in Rheumatology Magnetic Resonance Imaging Inflammatory Arthritis Working Group. Review: The utility of magnetic resonance imaging for assessing structural damage in randomized controlled trials in rheumatoid arthritis. Arthritis Rheum 2013;65:2513–23. PubMed

Tan YK, Conaghan PG. Imaging in rheumatoid arthritis. Best Pract Res Clin Rheumatol 2011;25:569–84. PubMed

van de Sande MG, van der Leij C, Lavini C, et al. . Characteristics of synovial inflammation in early arthritis analysed by pixel-by-pixel time-intensity curve shape analysis. Rheumatology (Oxford) 2012;51:1240–5. PubMed

Keystone E, Emery P, Peterfy CG, et al. . Rituximab inhibits structural joint damage in patients with rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitor therapies. Ann Rheum Dis 2009;68:216–21. PubMed

Peterfy CG, Olech E, Dicarlo JC, et al. . Monitoring cartilage loss in the hands and wrists in rheumatoid arthritis with magnetic resonance imaging in a multi-center clinical trial: IMPRESS (NCT00425932). Arthritis Res Ther 2013;15:R44. PubMed PMC

Genovese MC, Kavanaugh A, Weinblatt ME, et al. . An oral syk kinase inhibitor in the treatment of rheumatoid arthritis: a three-month randomized, placebo-controlled, phase II study in patients with active rheumatoid arthritis that did not respond to biologic agents. Arthritis Rheum 2011;63:337–45. PubMed

Haavardsholm EA, Ostergaard M, Ejbjerg BJ, et al. . Reliability and sensitivity to change of the OMERACT rheumatoid arthritis magnetic resonance imaging score in a multireader, longitudinal setting. Arthritis Rheum 2005;52:3860–7. PubMed

Ejbjerg B, Vestergaard A, Jacobsen S, et al. . The sensitivity to change for destructive joint damage by the Sharp/van der Heijde x-ray scores and 2 different MRI approaches. Arthritis Rheum 2003;50(Suppl 9):5172.

Peterfy CG, DiCarlo JC, Olech E, et al. . Evaluating joint-space narrowing and cartilage loss in rheumatoid arthritis by using MRI. Arthritis Res Ther 2012;14:R131. PubMed PMC

Genant HK. Methods of assessing radiographic change in rheumatoid arthritis. Am J Med 1983;75:35–47. PubMed

Peterfy C, Ostergaard M, Conaghan PG. MRI comes of age in RA clinical trials. Ann Rheum Dis 2013;72:794–6. PubMed

Rubbert-Roth A, Tak PP, Zerbini C, et al. . Efficacy and safety of various repeat treatment dosing regimens of rituximab in patients with active rheumatoid arthritis: Results of a phase III randomized study (MIRROR). Rheumatology (Oxford) 2010;49:1683–93. PubMed PMC

Emery P, Fleischmann R, Filipowicz-Sosnowska A, et al. . The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum 2006;54:1390–400. PubMed

Cohen SB, Emery P, Greenwald MW, et al. . Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 2006;54:2793–806. PubMed

Boumans MJ, Thurlings RM, Yeo L, et al. . Rituximab abrogates joint destruction in rheumatoid arthritis by inhibiting osteoclastogenesis. Ann Rheum Dis 2012;71:108–13. PubMed

Smolen JS, van der Heijde DM, Aletaha D, et al. . Progression of radiographic joint damage in rheumatoid arthritis: Independence of erosions and joint space narrowing. Ann Rheum Dis 2009;68:1535–40. PubMed

Cohen SB, Dore RK, Lane NE, et al. . Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial. Arthritis Rheum 2008;58:1299–309. PubMed

Bruynesteyn K, Boers M, Kostense P, et al. . Deciding on progression of joint damage in paired films of individual patients: smallest detectable difference or change. Ann Rheum Dis 2005;64:179–82. PubMed PMC

See more in PubMed

ClinicalTrials.gov
NCT00578305